Tradestie Institutional Equity Comparison Engine

PHIO vs CNSY โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

PHIO Overall Edge

PHIO Captures Institutional Edge (3โ€“0 Pillars ยท 8โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Phio Pharmaceuticals Corp. Common Stock (PHIO) driven by superior Valuation, Growth & Margin, Momentum & Technical. Fundamentally, PHIO trades at 0.3x Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus CNSY at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, PHIO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against CNSY sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner PHIO
PHIO 0.3x vs CNSY N/M Fwd P/E
Growth & Margin Winner PHIO
Op Margin 0.0% vs N/A ยท YoY +0.0% vs N/A
Momentum & Technical Winner PHIO
1Y -48.2% vs -79.5% ยท 52W Pos 2% vs 8%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
PHIO NASDAQ
Phio Pharmaceuticals Corp. Common Stock
Pharmaceutical Preparations
$0.74
-4.02% 1D
Market Cap $9.7M
1M Return -15.05%
1Y Return -48.25%
Forward P/E 0.3x
Unified AI Score
42.8 / 100 HOLD
Tech 26.0 Fund 48.0 Flow 50.0 Mom 64.0
CNSY US Equity
CNSY
Institutional Equity
$0.72
-24.24% 1D
Market Cap N/A
1M Return -57.65%
1Y Return -79.55%
Forward P/E N/M
Unified AI Score
47.6 / 100 HOLD
Tech 65.0 Fund 55.0 Flow 50.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: PHIO -48.25% CNSY -79.55% Spread: +51.39 pp (PHIO Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
PHIO TTM Op. Margin: 0.0% CNSY TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PHIO vs CNSY. Trailing 12-month operating profitability (PHIO 0.0% vs CNSY N/A) and valuation multiples (PHIO 0.3x vs CNSY N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: PHIO (8) vs CNSY (2)
Institutional Metric PHIO CNSY Criterion Row Winner
Market Capitalization Scale $9.7M N/A Larger Scale PHIO
Trailing P/E Ratio Valuation 0.3x N/M Lower Multiple PHIO
Forward P/E Ratio Valuation 0.3x N/M Lower Multiple PHIO
Revenue Growth (YoY) Growth +0.0% N/A Higher Growth PHIO
Operating Margin (TTM) Profitability 0.0% N/A Higher Margin PHIO
Net Profit Margin Profitability 0.0% N/A Higher Margin PHIO
Return on Equity (ROE) Capital Efficiency -113.7% N/A Higher ROE PHIO
52-Week Range Position Momentum 2% ($1โ€“$2) 8% ($0โ€“$4) Stronger Trend CNSY
Beta / 30D Volatility Risk Regime 1.05ฮฒ ยท 54% Vol 2.54ฮฒ ยท 228% Vol Lower Realized Risk PHIO
Unified Institutional Score Composite Signal 42.8 / 100 (HOLD) 47.6 / 100 (HOLD) Higher Composite CNSY

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full PHIO vs CNSY Buy Guide
PHIO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live PHIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CNSY UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live CNSY Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither PHIO nor CNSY registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.